TotalMarketCap

Cardiol Therapeutics

CRDLNasdaq CanadaHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$112.130 M

$0.93 -7.99%

Close of 6 Nov 2026

As of 6 Nov 2026, Cardiol Therapeutics (CRDL) has a market capitalization of $112.1M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

100,257,009

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #105Coherus OncologyCHRS$115.9M
  2. #106enGene TherapeuticsENGN$113.6M
  3. #107Cardiol TherapeuticsCRDL$112.1M
  4. #108Armata PharmaceuticalsARMP$111.2M
  5. #109HumacyteHUMA$108.3M

What if Cardiol Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$234,019.31

Per share 251,823× higher

Bitcoin $1.53T

$12,662.38

Per share 13,626× higher

Apple $5.02T

$41,569.40

Per share 44,732× higher

Or at a round number

$200.0M$500.0M$1.00B$2.00B

Where these numbers come from

Share counts and financials for Cardiol Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.